H.C. Wainwright Sticks to Their Buy Rating for Spectrum Pharmaceuticals (SPPI)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Spectrum Pharmaceuticals (SPPIResearch Report), with a price target of $6.00. The company’s shares closed yesterday at $0.46.

White covers the Healthcare sector, focusing on stocks such as Valneva, Spectrum Pharmaceuticals, and Aeglea Biotherapeutics. According to TipRanks, White has an average return of -22.1% and a 28.10% success rate on recommended stocks.

Spectrum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $3.83.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $2.11 and a one-year low of $0.36. Currently, Spectrum Pharmaceuticals has an average volume of 4.89M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.

Read More on SPPI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More